Results 21 to 30 of about 5,785,217 (307)
Biomolecules & Biomedicine, 2023 Quantification of measurable residual disease (MRD) correlates with the risk of leukemia recurrence in adults with B-cell acute lymphoblastic leukemia (ALL).
Lei-Ming Cao +16 more
doaj +1 more source
Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation [PDF]
, 2012 Background: Reconstitution of cytomegalovirus-specific CD3+CD8+ T cells (CMV-CTLs) after allogeneic hematopoietic stem cell transplantation (HSCT) is necessary to bring cytomegalovirus (CMV) reactivation under control. However, the parameters determining
Matthias Eder (21135) +56 more
core +2 more sources
Hematopoietic stem cells for transplantation [PDF]
Nature Immunology, 2002 Multiple sources of HSCs exist. Here, Verfaillie discusses the long-term engraftment capabilities of each source and the search for ex vivo expansion conditions to allow bulk culture for therapeutic HSC transplantation.
openaire +3 more sources
Hematopoietic chimerism after allogeneic stem cell transplantation : a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization [PDF]
, 2005 Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed mainly in patients with high-risk or advanced hematologic malignancies and congenital or acquired aplastic anemias.
Wachowiak, Jacek +13 more
core +2 more sources
Journal of Hematology & Oncology, 2017 Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t ...
Ya-Zhen Qin +14 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide.
Haina Wang +13 more
doaj +1 more source
Experimental Hematology & Oncology, 2017 Background Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have
Mauricio Sarmiento Maldonado +7 more
doaj +1 more source
Hematopoietic stem cell transplantation in thalassemia [PDF]
Bone Marrow Transplantation, 2008 SCT still remains the only cure currently available for patients with thalassemia. Results of transplants in this disease have steadily improved over the last two decades due to improvements in preventive strategies, effective control of transplant-related complications and development of new preparative regimens.
J, Gaziev, P, Sodani, G, Lucarelli
openaire +2 more sources
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma [PDF]
, 2004 We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10 ...
Mahendra, P +37 more
core +1 more source
Journal of Hematology & Oncology, 2019 The original article [1] contains two errors in the MRD Testing sub-section of the Methods:
Chen-Hua Yan +13 more
doaj +1 more source